Sunscreen TEA Review Deadlines In Limbo In House, Default Approvals Cut
This article was originally published in The Tan Sheet
The House Energy and Commerce Health subcommittee unanimously advances the Sunscreen Innovation Act to full committee, but provisions in the bill seeking a tight timeline for FDA’s review of sunscreen ingredient TEAs are in limbo, according to the Public Access to Sunscreens coalition of stakeholders.
You may also be interested in...
FDA advises BASF that the information the firm submitted is not sufficient to establish octyl triazone as GRASE. The agency’s third rejection this year of a sunscreen TEA could concern advocates on Capitol Hill and in the industry for using the process for adding ingredients to the OTC sunscreen monograph.
The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.
With color cosmetics sales on the decline in the US, retailer Ulta Beauty is confident marketers can inject some excitement and innovation into the category, but acknowledges the shift may take some time.